The additional reason was that the majority of enrolled patients with high-grade gliomas could rarely have gene loss or mutation including PTEN, which contributed to upregulation of PD-L1 expression [22] as well as different response to immune activity in the tumor microenvironment could lead to the non-uniform PD-L1 expression of tumor cells [26]. This evidence concerns the gene PTEN and glioma.